for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.

Official Title

A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy


Neoplasms Metastatic Cancer Neoplasm Metastasis Biopsy Checkpoint Inhibitor Therapy


You can join if…

Open to people ages 18 years and up

  • Response assessment of complete response (CR), partial response (PR), long stable disease (SD) for >3 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
  • Availability of tumor biopsy material extracted and preserved by the investigating site.

You CAN'T join if...

  • Participants taking CPI combination therapies with chemotherapy are not permitted.
  • Pregnant, lactating, or intending to become pregnant during the study.


  • UCSF Comp Canc Ctr not yet accepting patients
    San Francisco California 94115 United States
  • Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology accepting new patients
    Saint Louis Missouri 63108 United States
  • Sarah Cannon Cancer Center accepting new patients
    Arrington Tennessee 37014 United States
  • Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion accepting new patients
    New York New York 10032 United States
  • Dana-Farber Cancer Institute accepting new patients
    Boston Massachusetts 02215 United States


accepting new patients
Start Date
Completion Date
Hoffmann-La Roche
Phase 4
Study Type
Last Updated
August 6, 2018